© Reuters. FILE PHOTO: A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky
(Reuters) – Merck & Co stated on Monday the U.S. Meals and Drug Administration declined to approve its experimental drug for the therapy of continual cough and sought further data on the therapy’s effectiveness.
Merck stated it could meet with the company to debate subsequent steps on the oral drug, gefapixant.
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or harm because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote alerts contained inside this web site. Please be absolutely knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding varieties potential.